To enhance the therapeutic efficacy of pazopanib, a phase II TAPPAS trial investigated the combination of pazopanib with the anti-endoglin antibody carotuximab (TRC105), which targets Endoglin (CD105), highly expressed in tumor endothelium. The gene discussed is ENG; the disease is neoplasm.